clarithromycine for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
Tsiakos NCT04398004		NRa	clarithromycine	azithromycin plus hydroxychloroquine	COVID 19 hospitalized	serious	90/90	uncontrolled	[uncontrolled] End of treatment (composite endpoint for clinical improvement): 86.7% (78/90)
COVID-19 mild to moderate meta-analysis
Rashad (CLARI vs SoC)		RCT	clarithromycine	standard of care	COVID-19 mild to moderate	some concern	99/99	suggested	suggested 1.9-fold increase in radiologic improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID-19 mild to moderate meta-analysis